SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-003185
Filing Date
2022-01-06
Accepted
2022-01-06 08:31:01
Documents
14
Period of Report
2022-01-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d243232d8k.htm   iXBRL 8-K 27023
2 EX-99.1 d243232dex991.htm EX-99.1 24735
6 GRAPHIC g243232g0105112253984.jpg GRAPHIC 4760
  Complete submission text file 0001193125-22-003185.txt   189443

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20220106.xsd EX-101.SCH 2890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20220106_lab.xml EX-101.LAB 18906
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20220106_pre.xml EX-101.PRE 11861
8 EXTRACTED XBRL INSTANCE DOCUMENT d243232d8k_htm.xml XML 3497
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 22513706
SIC: 2836 Biological Products, (No Diagnostic Substances)